Literature DB >> 24754825

Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Jessica E Pittman1, Garry Cutting, Stephanie D Davis, Thomas Ferkol, Richard Boucher.   

Abstract

Cystic fibrosis (CF) is a life-limiting, monogenic disorder characterized by chronic sinopulmonary and gastrointestinal involvement. Progressive pulmonary disease leads to death in the majority of patients. Despite its well-defined molecular basis related to defects in the cystic fibrosis transmembrane conductance regulator anion transport channel, there are large gaps in our understanding of the origin of CF lung disease. Disease has been shown to be present in infancy, and there is mounting evidence that abnormalities begin in utero. Heterogeneity of clinical presentations and severity suggest that many factors involved in lung disease have yet to be fully elucidated. Although new advances in therapeutic treatments have shown promise in delaying disease progression, the prevention of pulmonary disease at its origin (primary prevention) should be a key goal of CF care. The objective of this workshop was to (1) review our understanding of the origins of CF lung disease, (2) determine gaps in the knowledge base that are most significant and most likely to enable prevention of CF lung disease, and (3) prioritize new research questions that will promote pulmonary health in both CF and other childhood lung diseases. The goal of this report is to provide recommendations for future research that will improve our understanding of pulmonary development in health and disease, improve outcome measures and biomarkers for early lung disease, and determine therapeutic targets and strategies to prevent the development of lung disease in children with CF.

Entities:  

Mesh:

Year:  2014        PMID: 24754825      PMCID: PMC5473656          DOI: 10.1513/AnnalsATS.201312-444LD

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  49 in total

1.  Improvement in pulmonary function following antibiotics in infants with cystic fibrosis.

Authors:  Jessica E Pittman; Robin C Johnson; Stephanie D Davis
Journal:  Pediatr Pulmonol       Date:  2011-10-18

2.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

Review 3.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

Authors:  Elliott C Dasenbrook; William Checkley; Christian A Merlo; Michael W Konstan; Noah Lechtzin; Michael P Boyle
Journal:  JAMA       Date:  2010-06-16       Impact factor: 56.272

5.  Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index.

Authors:  Yvonne Belessis; Barbara Dixon; Glenn Hawkins; John Pereira; Jenny Peat; Rebecca MacDonald; Penny Field; Andrew Numa; John Morton; Kei Lui; Adam Jaffe
Journal:  Am J Respir Crit Care Med       Date:  2012-02-09       Impact factor: 21.405

6.  Association between carrier screening and incidence of cystic fibrosis.

Authors:  Carlo Castellani; Luigi Picci; Anna Tamanini; Paolo Girardi; Paolo Rizzotti; Baroukh Maurice Assael
Journal:  JAMA       Date:  2009-12-16       Impact factor: 56.272

7.  Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

Authors:  Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan
Journal:  Am J Respir Crit Care Med       Date:  2009-04-16       Impact factor: 21.405

8.  The Th17 pathway in cystic fibrosis lung disease.

Authors:  Hui-Leng Tan; Nicolas Regamey; Sarah Brown; Andrew Bush; Clare M Lloyd; Jane C Davies
Journal:  Am J Respir Crit Care Med       Date:  2011-04-07       Impact factor: 21.405

9.  Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening.

Authors:  Graham L Hall; Karla M Logie; Faith Parsons; Sven M Schulzke; Gary Nolan; Conor Murray; Sarath Ranganathan; Phil Robinson; Peter D Sly; Stephen M Stick; Luke Berry; Luke Garratt; John Massie; Lauren Mott; Srinivas Poreddy; Shannon Simpson
Journal:  PLoS One       Date:  2011-08-19       Impact factor: 3.240

10.  Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung.

Authors:  Alejandro A Pezzulo; Xiao Xiao Tang; Mark J Hoegger; Mahmoud H Abou Alaiwa; Shyam Ramachandran; Thomas O Moninger; Phillip H Karp; Christine L Wohlford-Lenane; Henk P Haagsman; Martin van Eijk; Botond Bánfi; Alexander R Horswill; David A Stoltz; Paul B McCray; Michael J Welsh; Joseph Zabner
Journal:  Nature       Date:  2012-07-04       Impact factor: 49.962

View more
  14 in total

1.  Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.

Authors:  Michael D Kim; Nathalie Baumlin; Makoto Yoshida; Deepika Polineni; Sebastian F Salathe; Joseph K David; Charles A Peloquin; Adam Wanner; John S Dennis; Juliette Sailland; Philip Whitney; Frank T Horrigan; Juan R Sabater; William M Abraham; Matthias Salathe
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

2.  Association of Antibiotics, Airway Microbiome, and Inflammation in Infants with Cystic Fibrosis.

Authors:  Jessica E Pittman; Kristine M Wylie; Kathryn Akers; Gregory A Storch; Joseph Hatch; Jane Quante; Katherine B Frayman; Nadeene Clarke; Miriam Davis; Stephen M Stick; Graham L Hall; Gregory Montgomery; Sarath Ranganathan; Stephanie D Davis; Thomas W Ferkol
Journal:  Ann Am Thorac Soc       Date:  2017-10

3.  Reply: primary and secondary prevention of chronic obstructive pulmonary disease: where to next?

Authors:  James P Kiley; Gary H Gibbons
Journal:  Am J Respir Crit Care Med       Date:  2014-10-01       Impact factor: 21.405

Review 4.  Executive Summary: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  William W Busse; Serpil C Erzurum; Carol J Blaisdell; Patricia Noel
Journal:  Ann Am Thorac Soc       Date:  2014-04

Review 5.  Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations.

Authors:  L Keith Scott; Robert Toner
Journal:  Lung       Date:  2017-06-16       Impact factor: 2.584

6.  Altered Stool Microbiota of Infants with Cystic Fibrosis Shows a Reduction in Genera Associated with Immune Programming from Birth.

Authors:  Katherine M Antosca; Diana A Chernikova; Courtney E Price; Kathryn L Ruoff; Kewei Li; Margaret F Guill; Natalie R Sontag; Hilary G Morrison; Shuyu Hao; Mitchell L Drumm; Todd A MacKenzie; Dana B Dorman; Lynn M Feenan; Molly A Williams; John Dessaint; Irene H Yuan; Brian J Aldrich; Lisa A Moulton; Lily Ting; Ana Martinez-Del Campo; Edward J Stewart; Margaret R Karagas; George A O'Toole; Juliette C Madan
Journal:  J Bacteriol       Date:  2019-07-24       Impact factor: 3.490

7.  Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation.

Authors:  Theresa A Laguna; Cavan S Reilly; Cynthia B Williams; Cole Welchlin; Chris H Wendt
Journal:  Pediatr Pulmonol       Date:  2015-06-26

Review 8.  Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?

Authors:  Sarath C Ranganathan; Graham L Hall; Peter D Sly; Stephen M Stick; Tonia A Douglas
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

Review 9.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

10.  An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research.

Authors:  Eric S White; Zea Borok; Kevin K Brown; Oliver Eickelberg; Andreas Guenther; R Gisli Jenkins; Martin Kolb; Fernando J Martinez; Jesse Roman; Patricia Sime
Journal:  Am J Respir Crit Care Med       Date:  2016-04-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.